Biomedical Engineering Reference
In-Depth Information
060712-7
3: MRM of 13 Channels ES+
315>85.9
1.63e5
4.66
100
Clomipramine
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
3:MRM of 13 Channels ES+
301.1>71.8
1.61e5
4.59
100
Norclomipramine
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
3: MRM of 13 Channels ES+
310.1>43.7
6.62e4
4.47
100
Fluoxetine
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
3: MRM of 13 Channels ES+
306>159.1
5.23e4
4.45
100
Sertraline
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
3: MRM of 13 Channels ES+
296>134.1
3.38e4
4.34
100
Norfluoxetine
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
2: MRM of 15 Channels ES+
278>90.8
9.33e4
3.85
100
Amitriptyline
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
2: MRM of 15 Channels ES+
319>70.8
5.40e4
3.82
Fluvoxamine
100
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
2: MRM of 15 Channels ES+
264.2>233.3
4.72e4
3.74
100
Nortriptyline
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
2:MRM of 15 Channels ES+
330>69.7
3.23e4
3.64
100
Paroxetine
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
2:MRM of 15 Channels ES+
281.1>85.9
2.93e5
3.54
100
Imipramine
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
2:MRM of 15 Channels ES+
267>71.8
2.36e5
3.46
100
Desipramine
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
1: MRM of 4 Channels ES+
325.1>109.1
1.59e5
2.66
100
0
Citalopram
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
060712-7
1: MRM of 4 Channels ES+
278.1>57.8
2.25e5
0.77
Venlafaxine
100
0
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
5.50
6.00
Fig. 2
Chromatograms of the quantitative transitions for the 13 antidepressants included in the
LC-MS/MS method in oral fluid at the LLOQ (2 ng/mL) (
Source
: From de Castro A et al. (2008)
J Pharm Biomed Anal
.
48:183. With permission)
